Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
about
Therapy of murine squamous cell carcinomas with 2-difluoromethylornithineTranslational development of difluoromethylornithine (DFMO) for the treatment of neuroblastomaHerbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.Apigenin Inhibits Human SW620 Cell Growth by Targeting Polyamine Catabolism.The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplificationMelding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents.Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.The mechanisms by which polyamines accelerate tumor spread.Survival following adjuvant PCV or temozolomide for anaplastic astrocytomaImpact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.CNS Anticancer Drug Discovery and Development Conference White Paper.Knockdown of antizyme inhibitor decreases prostate tumor growth in vivoFive-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma.In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells.The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trialGliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.Polyamine transport as a target for treatment of Pneumocystis pneumonia.Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.Design of polyamine-based therapeutic agents: new targets and new directionsTissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.B-cell populations are expanded in breast cancer patients compared with healthy controls.Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.
P2860
Q24797178-31F91FFC-7F79-42A9-9000-2921CB28FC8DQ26770306-0ED1AE84-A191-43EA-A1CD-6A06A635D289Q30362087-F37962CC-158D-464A-A731-ED3805282C54Q33517982-AFEDC078-EB85-48FD-95FB-1EB2598B69FBQ33720933-7869E328-F3E7-4306-A389-8287F1623275Q33761692-3B0E442C-D9FC-41A0-AEB2-840961A7E5AAQ33827019-83BA38C4-97AC-4255-8B20-8AA12EAC07C5Q34618239-0B9D87C4-9B27-4FC9-B2D4-0F1048BF7DB2Q35046326-777A5B21-F711-40AC-8452-178E00EEA90EQ35238424-9C790872-FF92-497D-9312-C1901FD01542Q35505118-89EEE247-5046-47C0-8631-E67701530A3CQ35800632-37B2E46F-0D60-4F00-843D-EFA06E22A152Q35891348-48C29506-D9BB-4BA1-9B36-CC81F870182FQ36089590-33006514-EC63-47F0-8EF0-2EA7C6F5282AQ36638469-C3D104C1-E2E8-4CFC-9B0B-6BEA3D8ABDE9Q36732622-900729C7-23AE-4173-B772-EF1E5E3BEB24Q36790732-BDF00CBC-7263-401D-B47D-9A24B56CC4E4Q36836192-0AC6AA00-2421-4A27-B366-196BB761CF68Q37174245-FD1EA774-D707-4BD1-B703-4ADEC5EBD707Q37318415-6923A01D-D609-491F-98A1-E093F3B1623DQ37450672-4F6B3DD1-9967-40CC-9D90-03E6BDAE25CFQ37605450-7FD38EB9-466D-4802-BDFA-2CC29D967E09Q37679982-E46A2CBE-2A2D-4E4E-B41D-6C5711D8A422Q38324120-9B97A170-3328-4483-BBEB-667ED7A324A2Q41107342-989BFDE7-3244-4170-A007-29E763236B85Q48181967-DD9E2B97-950A-42BE-96FF-0DEBBC008AC0Q49600966-EEC0731C-5CA8-4DCB-B6A8-03D6544B014C
P2860
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@ast
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@en
type
label
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@ast
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@en
prefLabel
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@ast
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@en
P2093
P1476
Phase III randomized study of ...... us PCV for anaplastic gliomas.
@en
P2093
Ali Choucair
Athanassios P Kyritsis
Hyung-Woo Kim
Janet M Bruner
Kenneth R Hess
Kurt A Jaeckle
Mary Jo Gleason
Michael D Prados
Patrick J Flynn
Sandra Ictech
P304
P407
P577
2003-03-01T00:00:00Z